NITO News & Events

N2OFF highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation. The study, titled "SLC25A mitochondrial carriers as biomarkers and therapeutic targets of spaceflight-induced dysfunction: the ADP/ATP carrier as a structural case study," was published online on December 30. The work integrates transcriptomic data from NASA's Open Science Data Repository, examining the expression of 53 SLC25A genes in osteocytes, human bone marrow-derived mesenchymal stem cells, and mouse brain tissue exposed to microgravity and spaceflight-related stressors. The analysis identified differential regulation of multiple SLC25A carriers under spaceflight conditions, supporting their potential utility as biomarkers of mitochondrial and metabolic dysfunction. The ADP/ATP carrier AAC3 was further examined as a structural case study, based on comparative modeling and structure-function analyses to illustrate how carrier conformational features may be targeted to rescue mitochondrial bioenergetics under stress. While this independent academic research- conducted in collaboration with the University of Bari "Aldo Moro" and the University of Pittsburgh-was not performed under MitoCareX Bio's auspices, it directly aligns with the Company's core scientific area of focus on mitochondrial carrier biology. MitoCareX Bio applies proprietary approaches, including the MITOLINE algorithm to virtually model, screen and validate small-molecule modulators targeting the SLC25A family of mitochondrial carriers. These proteins, central to cellular energy metabolism, play central roles in hard-to-treat indications including in several types of cancer, metabolic diseases related to the metabolic syndrome, and are also implicated in rare inherited disorders associated with neuromuscular degeneration, which share mechanistic similarities with physiological alterations observed in astronauts.

N2OFF announced that MitoCareX Bio has shown preliminary in vitro data demonstrating inhibition of pro--inflammatory responses in human immune cells using its proprietary discovery platform. Using MITOLINE-derived models, MitoCareX has assembled a focused library of small-molecule candidates that is now being evaluated in a suite of proprietary in-vitro assays designed to capture mitochondrial function, inflammatory signalling, and metabolic readouts. The newly reported in vitro data show that selected candidates reduce key inflammatory markers in human immune cells, providing an initial line of evidence that mitochondrial carrier modulation can deliver anti-inflammatory benefit in human-relevant systems. These results support further in vivo validation and lead optimization across multiple inflammatory metabolic disease indications including diseases related to the metabolic syndrome.

N2OFF highlighted a newly published peer-reviewed study co-authored by Prof. Ciro Leonardo Pierri, co-founder of MitoCareX Bio, N2OFF's wholly-owned subsidiary. The article, appearing in the Journal of Translational Medicine, investigates SLC25A mitochondrial carriers as potential biomarkers and therapeutic targets for dysfunctions induced by spaceflight conditions, including microgravity and cosmic radiation. The study, titled "SLC25A mitochondrial carriers as biomarkers and therapeutic targets of spaceflight-induced dysfunction: the ADP/ATP carrier as a structural case study," was published online on December 30, 2025. The work integrates transcriptomic data from NASA's Open Science Data Repository, examining the expression of 53 SLC25A genes in osteocytes, human bone marrow-derived mesenchymal stem cells, and mouse brain tissue exposed to microgravity and spaceflight-related stressors.

N2OFF announced advancement in its European portfolio via its partnership with Solterra Renewable Energy. As announced on December 29, 2025, key milestones in Germany project, which includes solar energy PV and storage assets, have reduced permitting risks, unlocked value through smart capital deployment, and positioned projects for compelling monetization optionality. Reduction in permitting and regulatory risk across core European assets; Advanced payment of $340,000 and receiving favourable terms in the project's profit stake; Approximately $1.7 million in project-level value creation achieved through disciplined renegotiation of development economicsEnhanced monetization optionality, with multiple high-visibility pathways to value realization beginning in H2 2026. N2OFF's flagship German solar project has advanced into the final stages of the permitting process and remains firmly on track toward expected approval in Q3 2026. The first public consultation phase is nearing completion with no objections or material modification requests to date, a strong indicator of regulatory alignment, community acceptance, and planning integrity. Submission of the draft zoning plan for the final consultation phase is scheduled for late January 2026 following the holiday period, maintaining a clear development timeline. In a demonstration of proactive value optimization, Solterra has indicated that an amendment to the development agreement was executed last week. Solterra will receive approximately $340,000 in advance funding to fuel faster progress, in exchange for a EUR 11,000 per MW reduction in development fees, thereby increasing potential profit with approximately $ 1.7 million.